Previous Close | 0.0450 |
Open | 0.0500 |
Bid | 0.0450 x N/A |
Ask | 0.0500 x N/A |
Day's Range | 0.0500 - 0.0500 |
52 Week Range | 0.0400 - 0.1350 |
Volume | |
Avg. Volume | 171,007 |
Market Cap | 16.69M |
Beta (5Y Monthly) | 1.69 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1900 |
Earnings Date | May 16, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for VIVO.TO
Toronto, Ontario--(Newsfile Corp. - July 22, 2022) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQX: VVCIF) ("VIVO" or the "Company"), a leading provider of medical cannabis products and patient services, and holder of licences under the Cannabis Act through its wholly-owned subsidiaries, Canna Farms Limited ("Canna Farms"), ABcann Medicinals Inc., today announced that Canna Farms has received a Research Licence from Health Canada allowing it to possess cannabis for the purpose of research. The Research
Toronto, Ontario--(Newsfile Corp. - July 2, 2022) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQB: VVCIF) ("VIVO" or the "Company"), a leading provider of premium cannabis products and services, is pleased to announce the results of its annual general and special meeting of shareholders held today (the "Meeting"). As announced this morning, at the Meeting, shareholders approved fixing the number of directors at five, and the election of Ray Laflamme, Glen Huber, Shai Altman, Eric ...
Toronto, Ontario--(Newsfile Corp. - June 3, 2022) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQX: VVCIF) ("VIVO" or the "Company"), a leading provider of medical cannabis products and patient services, and holder of licenses under the Cannabis Act through its wholly-owned subsidiaries, Canna Farms Limited ("Canna Farms"), ABcann Medicinals Inc., today announced results from its first study investigating how medical cannabis impacts anxiety and depression outcomes. The publication, entitled "Medical can